Sucampo Pharmaceuticals, Inc. (delisted) (SCMP) Quote

Sucampo Shareholders Upset Over Merger Bid - (via NewsPoints Desk)
December 28, 2017
Tags: NewsPoints Sucampo Mallinkrodt United States Corporate Affairs Mergers & Acquisitions

A group of Sucampo Pharmaceuticals Inc. shareholders are attempting
to block the $1.2 billion purchase of the company by Mallinkrodt plc.

The shareholders allege that the purchase price $18 per share is insufficient in light of the company's growth
prospects and that deal-protection clauses in the merger agreement preclude other companies from submitting successful competing offers. In addition, shareholders allege that senior management obtained personal benefits for their own self interests
in agreeing to sell the company that are not being shared with common stockholders.

Sucampo did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Sucampo for more information as to how you can participate
with shareholders to get a higher price at no cost or expense
call toll free 800.511.7037 or contact@tripplevy.com

Yeehaw, the SCMP buyout.. Finally!

Why the spike to $17.70 today?

Been holding since $10.31

1st QTR EPS estimate $0.26 giving $0.69 TTM giving a PE of 14.5

Roth Capital set a $27.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, March 11th.
https://www.thecerbatgem.com/2017/03/23/sucampo-pharmaceuticals-inc-scmp-receives-consensus-rating-of-buy-from-analysts.html

Mizuho reiterated a “buy” rating and issued a $16.00 target price on shares of Sucampo Pharmaceuticals in a research note on Monday, March 6th. Zacks Investment Research downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 21st. Maxim Group lifted their target price on Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, November 15th.

https://www.chaffeybreeze.com/2017/03/11/sucampo-pharmaceuticals-inc-scmp-stock-rating-reaffirmed-by-jefferies-group-llc.html

$17.29 target price per FINVIZ
http://finviz.com/quote.ashx?t=SCMP

For 2016, earnings came in at $1.51 per share compared with earnings of 96 cents per share in 2015. Results also beat the Zacks Consensus Estimate of $1.22.

http://finance.yahoo.com/news/sucampo-scmp-beats-q4-earnings-155303108.html

2017 Guidance Reaffirmed

Sucampo reaffirmed its guidance for the full year 2017. The company expects total revenue in the range of $220.0 million to $230.0 million. The Zacks Consensus Estimate for 2017 is $227.28 million.

The company expects adjusted net income in the range of $80.0 million to $90.0 million, and adjusted earnings in the range of $1.35 to $1.50
The company forecasts adjusted EBITDA of $145.0 million to $155.0 million. Adjusted EBITDA guidance excludes stock option related costs of $6.0 million.

http://finance.yahoo.com/news/sucampo-scmp-beats-q4-earnings-155303108.html

SCMP- Always has been my favorite in this space instead of IRWD or SGYP. Look at all those shares outstanding in SGYP..

Back in at 10.93

In at 11.32

SCMP bullish 12.05

$SCMP recent news/filings

bearish 10.35

## source: finance.yahoo.com

$SCMP charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SCMP company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SCMP/company-info
Ticker: $SCMP
OTC Market Place: Not Available
CIK code: 0001365216
Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com
Incorporated In:

$SCMP share structure

## source: otcmarkets.com

Market Value: $471,332,624 a/o Mar 18, 2016
Shares Outstanding: 45,539,384 a/o Mar 01, 2016
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$SCMP extra dd links

Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SCMP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SCMP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SCMP+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/news - http://finance.yahoo.com/q/h?s=SCMP+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SCMP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SCMP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SCMP
DTCC (dtcc.com): http://search2.dtcc.com/?q=Sucampo+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Sucampo+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Sucampo+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.sucamp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.sucamp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.sucamp.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SCMP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001365216&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SCMP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SCMP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SCMP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SCMP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SCMP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SCMP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SCMP+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SCMP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SCMP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SCMP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SCMP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SCMP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SCMP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SCMP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SCMP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SCMP



$SCMP DD Notes ~ http://www.ddnotesmaker.com/SCMP

$SCMP recent news/filings

bullish 17.02
lots of previous breakouts, support bounces, and gaps up at this level
dojis and hammer candles

## source: finance.yahoo.com

Wed, 11 Nov 2015 18:04:20 GMT ~ SUCAMPO PHARMACEUTICALS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=scmp
*********************************************************

Mon, 09 Nov 2015 13:00:00 GMT ~ Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors

[PR Newswire] - SAN DIEGO, Nov. 9, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, today announced that Peter Greenleaf has been appointed to the Company's Board of Directors, effective immediately.

read full: http://finance.yahoo.com/news/mast-therapeutics-announces-appointment-peter-130000296.html
*********************************************************

Thu, 05 Nov 2015 21:21:09 GMT ~ Sucampo (SCMP) Misses on Q3 Earnings, Focus on Amitiza


read full: http://finance.yahoo.com/news/sucampo-scmp-misses-q3-earnings-212109717.html
*********************************************************

Wed, 04 Nov 2015 18:05:36 GMT ~ Edited Transcript of SCMP earnings conference call or presentation 4-Nov-15 1:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-scmp-earnings-conference-180536033.html
*********************************************************

Wed, 04 Nov 2015 13:30:00 GMT ~ Sucampo Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today


read full: http://biz.yahoo.com/cc/8/147718.html
*********************************************************

$SCMP charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SCMP company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SCMP/company-info
Ticker: $SCMP
OTC Market Place: Not Available
CIK code: 0001365216
Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com
Incorporated In:

$SCMP share structure

## source: otcmarkets.com

Market Value: $771,294,846 a/o Nov 20, 2015
Shares Outstanding: 45,316,971 a/o Nov 01, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$SCMP extra dd links

Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SCMP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SCMP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SCMP+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/news - http://finance.yahoo.com/q/h?s=SCMP+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SCMP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SCMP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SCMP
DTCC (dtcc.com): http://search2.dtcc.com/?q=Sucampo+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Sucampo+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Sucampo+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.sucamp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.sucamp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.sucamp.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SCMP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001365216&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SCMP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SCMP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SCMP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SCMP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SCMP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SCMP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SCMP+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SCMP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SCMP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SCMP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SCMP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SCMP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SCMP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SCMP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SCMP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SCMP



$SCMP DD Notes ~ http://www.ddnotesmaker.com/SCMP

$SCMP recent news/filings

bullish
close > 1 and average volume > 100k

## source: finance.yahoo.com

Fri, 28 Aug 2015 20:34:00 GMT ~ Ambarella Leads 4 Top Stocks With Rising Estimates


read full: http://news.investors.com/082815-768682-ambarella-illumina-dr-horton-earnings-estimates-up.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Thu, 27 Aug 2015 22:38:00 GMT ~ Stock Market Today - 08/27/2015


read full: http://finance.yahoo.com/video/stock-market-today-08-27-223800837.html
*********************************************************

Thu, 27 Aug 2015 19:55:07 GMT ~ Sucampo to Acquire R-Tech Ueno for About $278 Million


read full: http://finance.yahoo.com/news/sucampo-acquire-r-tech-ueno-195507118.html
*********************************************************

Thu, 27 Aug 2015 09:45:08 GMT ~ Why does Sucampo want to acquire its founders' Japanese company? Transformation.


read full: http://www.bizjournals.com/washington/blog/2015/08/why-does-sucampo-want-to-acquire-its-founders.html?ana=yahoo
*********************************************************

Wed, 26 Aug 2015 15:45:25 GMT ~ Bethesda pharmaceutical makes $278 million all-cash offer for Japanese company


read full: http://www.bizjournals.com/washington/blog/techflash/2015/08/bethesda-pharmaceutical-makes-278-million-all-cash.html?ana=yahoo
*********************************************************

$SCMP charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SCMP company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SCMP/company-info
Ticker: $SCMP
OTC Market Place: Not Available
CIK code: 0001365216
Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com
Incorporated In:

$SCMP share structure

## source: otcmarkets.com

Market Value: $1,279,511,971 a/o Aug 28, 2015
Shares Outstanding: 45,244,412 a/o Aug 02, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$SCMP extra dd links

Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SCMP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SCMP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SCMP+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/news - http://finance.yahoo.com/q/h?s=SCMP+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SCMP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SCMP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SCMP
DTCC (dtcc.com): http://search2.dtcc.com/?q=Sucampo+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Sucampo+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Sucampo+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.sucamp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.sucamp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.sucamp.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SCMP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001365216&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SCMP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SCMP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SCMP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SCMP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SCMP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SCMP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SCMP+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SCMP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SCMP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SCMP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SCMP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SCMP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SCMP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SCMP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SCMP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SCMP



$SCMP DD Notes ~ http://www.ddnotesmaker.com/SCMP

And shine again today!

XBI: Down 2.5%
SCMP: Up 3.95%

That's strength right there!

One of the few stocks to shine in this sell off climate. (IBX down 5% today, SCMP up 7%)

The gist of the earnings call:
Sucampo (NASDAQ:SCMP): Q2 EPS of $0.21 beats by $0.06.
Revenue of $34.88M (+44.9% Y/Y) beats by $2.98M.

And more to come:
"In Europe; Austria, Germany, and Italy issued national marketing authorizations for AMITIZA for the treatment of chronic idiopathic constipation, joining, Ireland, Luxemburg, the Netherlands, and Belgium, and we expect Spain to issue national marketing authorization by the end of this year. For Europe, Takeda continues to work on pricing and reimbursement assessments to inform their launch plans and sequencing, and continues to sell AMITIZA in Switzerland and the United Kingdom."

Analyst 'forecast' positive:

Change Over Previous Year
'15 '16 '17
54.3% 32.9% 81.7%

All those projections was the reason I opened my position. It's the 15% shorts that bother me but I'm still in for the long term.

Thanks, M

Go $SCMP

Growth EPS Projections:
'15 '16 '17
48.3% 32.9% 67.1%

With a P/E of about 38 and great stats (RoE, RoA, Profit, etc...) besides that. What a Peter Lynch type buy (great company with a great PEG). And they meet the projections well enough! An expensive company but in this context, I'm keeping it :)

A dip then (a bad one; was due to a downgrade by one analyst I would gather), a great Hold for a long time in my view. Of course, no crystal ball here.

Wow! Went off yesterday and when I came home we had tanked.
Big time!

What happened?

EPS up and we loose almost 20%. Any chance of a recovery soon?

Go $SCMP


M

SCMP EPS: +600%!!!

http://seekingalpha.com/news/2494006-sucampo-esrnings-up-700-percent-in-q1

Sucampo Q1 results:
Revenues: $29.5M (+32.9%);
COGS: $6.1M (+79.4%);
R&D Expense: $6.8M (+33.3%);
SG&A: $6.9M (-36.7%);
Operating Income: $9.7M (+259.3%);
Net Income: $6.4M (+700.0%);
EPS: $0.14 (+600.0%);
Quick Assets: $59.6M (-16.8%).
2015 Guidance:
GAAP Net Income: $25M - 30M; GAAP EPS: $0.55 - 0.65.

Started investing late 2013, and so far, it's been good and continues to be good :)

CHART is very simple
green vertical = trend up like now
red vertical = trend down

*** SCMP is interesting because it is the only pham stock with eps and div that is still on A BUY

That is good when market turns up. IMHO.

Zacks Rank #1 (Strong Buy

Investors certainly have to be happy with Sucampo Pharmaceuticals, Inc. (SCMP) and its short term performance. After all, the stock has jumped by 38.6% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for SCMP?

While we can never know for sure, it is pretty encouraging that estimates for SCMP have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #1 (Strong Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks.

SCMP D

SCMP D is interesting because it is the only pham stock with eps and div that is still on BUY
That is good when market turns up. IMHO.

$SCMP DD Notes ~ http://www.ddnotesmaker.com/SCMP

bullish
good volume

$SCMP recent news/filings

## source: finance.yahoo.com

Fri, 14 Nov 2014 18:04:52 GMT ~ SUCAMPO PHARMACEUTICALS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=scmp
*********************************************************

Fri, 14 Nov 2014 13:13:08 GMT ~ Flamel Technologies (FLML) in Focus: Stock Rises 11%


read full: http://finance.yahoo.com/news/flamel-technologies-flml-focus-stock-131308588.html
*********************************************************

Fri, 14 Nov 2014 12:11:44 GMT ~ Can The Uptrend Continue for Sucampo Pharmaceuticals (SCMP)?


read full: http://finance.yahoo.com/news/uptrend-continue-sucampo-pharmaceuticals-scmp-121144298.html
*********************************************************

Thu, 13 Nov 2014 20:30:02 GMT ~ Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation


read full: http://finance.yahoo.com/news/sucampo-takeda-sue-dr-reddys-203002593.html
*********************************************************

Thu, 13 Nov 2014 11:51:19 GMT ~ Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher


read full: http://finance.yahoo.com/news/sucampo-scmp-worth-watching-stock-115119444.html
*********************************************************


$SCMP charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$SCMP company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SCMP/company-info
Ticker: $SCMP
OTC Market Place: Not Available
CIK code: 0001365216
Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com
Incorporated In:


$SCMP share structure

## source: otcmarkets.com

Market Value: $517,352,740 a/o Nov 21, 2014
Shares Outstanding: 44,293,899 a/o Jul 25, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$SCMP extra dd links

Company name: Sucampo Pharmaceuticals, Inc.
Company website: http://www.sucamp.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SCMP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SCMP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SCMP+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/news - http://finance.yahoo.com/q/h?s=SCMP+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SCMP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SCMP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SCMP
DTCC (dtcc.com): http://search2.dtcc.com/?q=Sucampo+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Sucampo+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Sucampo+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.sucamp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.sucamp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.sucamp.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SCMP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001365216&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SCMP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SCMP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SCMP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SCMP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SCMP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SCMP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SCMP+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SCMP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SCMP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SCMP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SCMP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SCMP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SCMP/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SCMP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SCMP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SCMP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SCMP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SCMP



$SCMP DD Notes ~ http://www.ddnotesmaker.com/SCMP

Finally on fire. But, I sold today after a run from sub $5.

Finally on fire. But, I sold today after a run from sub $5.

What is going on with everyone! Do I go long? Do I short? The stock is up super fat, and it has done this three times before!!! I'm totally buying more!!!

$SCMP Favorable Patent Settlement With Par – A Strong Win For Sucampo, Says Roth Capital http://www.smarteranalyst.com/2014/10/10/favorable-patent-settlement-par-strong-win-sucampo-says-roth-capital/

Cantor Fitzgerald Reiterates Buy On Sucampo Following 2Q14 Results; Keeps $12 PT http://www.smarteranalyst.com/2014/08/07/cantor-fitzgerald-reiterates-buy-on-sucampo-following-2q14-results-keeps-12-pt/

SCMP $8.50 x 8.55

the DOW way overdue for a correction, and BIO's are usually as affected by it, especially with good news

New 52 week high today, in a down DOW -179 market..

Q313 US net sales of constipation drug Amitiza (by US partner Takeda) reached $72.5m (+1.4%) and we estimate FY13 sales at $280m. Amitiza is the only oral drug available for opioid-induced constipation, a significant opportunity. Amitiza holds further potential from its commercial roll-out in Japan (marketed by Abbott Japan) and in Europe (directly in the UK and Switzerland; with further partnerships possible). Sucampo is planning a Phase III programme for Amitiza in paediatric patients and has started a pivotal study with a liquid formulation. Rescula (unoprostone) is available for glaucoma in the US (since Feb 2013), and is being studied in Japan in a Phase III trial for retinitis pigmentosa, a significant unmet need.

6:50AM Sucampo Pharma reports results from Phase 2a study of intravenous ion channel activator for lumbar spinal stenosis; statistically significant improvement observed in visual analog scale pain (SCMP) 9.05 :

Co announced the results of its double-blind, placebo-controlled Phase 2a proof of concept study evaluating safety and efficacy of an intravenously (IV) administered compound of the company's proprietary ion channel activator program in patients with lumbar spinal stenosis (LSS). A responder analysis of data from the trial revealed that patients receiving the ion channel activator experienced a statistically significant improvement in pain, as determined by improvements in the visual analog scale (VAS) score, versus placebo (94.4% versus 62.5%; p=0.035).
Improvements were also observed in the primary and other efficacy measures, including pain-associated quality of life measures for patients treated with the ion channel activator, although the extent of improvement was not statistically significant.
The ion channel activator was well-tolerated and was not associated with serious adverse events. Additionally, no worsening of any of the efficacy measures in the active group was recorded.

Sucampo Reports Results from Phase 2a Study of Intravenous Ion Channel Activator for Lumbar Spinal Stenosis
Statistically Significant Improvement Observed in Visual Analog Scale (VAS) Pain

Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation







Print


Alert



Sucampo Pharmaceuticals - Class A (MM) (NASDAQ:SCMP)
Intraday Stock Chart

Today : Tuesday 17 December 2013
Click Here for more Sucampo Pharmaceuticals - Class A (MM) Charts.
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals ("Takeda") today announced the initiation of a global pivotal Phase 3 clinical program of lubiprostone in pediatric functional constipation. Functional constipation is a very common gastrointestinal complaint in children and is on the rise. An analysis of longitudinal data in the United States showed a nearly 4-fold increase in rates of constipation over the last decade.1



Takeda Pharmaceuticals U.S.A., Inc. logo






Lubiprostone is the world's first chloride channel activator that increases intestinal fluid secretion, softens stools and increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. This Phase 3 program was preceded by an open-label trial in 124 patients aged 3 to 17 years, which suggested that lubiprostone warrants further investigation as a potential treatment for children and adolescents with functional constipation.

Estimates of the prevalence rate of functional constipation in the pediatric population worldwide have varied from 4 to 37%.2 Only 50 to 70% of children with functional constipation demonstrate long-term improvement with the current treatments.3

"I am very pleased to be participating in this pivotal program which will study lubiprostone for pediatric functional constipation," said Paul Hyman, MD, Investigator and Professor of Pediatrics, Division Head, Gastroenterology, Children's Hospital at New Orleans, Louisiana State University Health Science Center. "There is an unmet need for alternatives to traditional laxative therapy in the pediatric population, and there are currently no prescription products indicated for long-term use in this population. We look forward to conducting this study to determine whether lubiprostone may be a valuable treatment alternative for these pediatric patients."

This Phase 3 program consists of two well-controlled pivotal studies with similar design – one testing lubiprostone capsules in patients 6 to 17 years of age and another testing lubiprostone liquid formulation in patients aged 6 months to under 6 years. Sucampo also plans to evaluate the long-term safety of lubiprostone in these populations through two open-label extension studies.

The first Phase 3 trial in the program, which has just been initiated, is a randomized, placebo-controlled, double-blind study of the efficacy, safety and pharmacokinetics of lubiprostone in pediatric subjects between the ages of 6 to 17. The trial is expected to enroll more than 500 patients with pediatric functional constipation at up to 100 sites across the United States, Canada, and Europe. Subjects will be treated for 12 weeks with weight-based dosages of 12 mcg or 24 mcg twice daily (BID). The primary endpoint for this trial is overall spontaneous bowel movement (SBM) response. An SBM is a bowel movement that occurs without the use of another constipation treatment such as a laxative, enema, or suppository, during the 24 hours prior to occurrence.

Sucampo plans to file a supplemental new drug application with the U.S. Food and Drug Administration following program completion, which is anticipated by early 2016.

About Pediatric Functional Constipation

The symptoms of pediatric functional constipation include infrequent bowel movements (BMs), hard stools, large diameter stools and painful passage of stools. Rome III diagnostic criteria for childhood functional constipation dictate that such symptoms occur at least once per week for at least 2 months prior to diagnosis. Children may also experience fecal retention due to withholding.1 There is a tendency to avoid defecation and withhold BMs as a result of pain experienced from the passage of large stools. This withholding of BMs can result in episodes of fecal incontinence. Ninety percent of pediatric constipation is functional constipation and it occurs in all age groups.4

About lubiprostone

Amitiza® (lubiprostone) capsules are indicated for the treatment of chronic idiopathic constipation (CIC) in adults and opioid induced constipation (OIC) in adults with chronic, non-cancer pain (24 mcg twice daily). The effectiveness in patients with OIC taking diphenylheptane opioids (e.g., methadone) has not been established. Amitiza is also indicated for irritable bowel syndrome with constipation (IBS-C) in women > 18 years old (8 mcg twice daily).

Important Safety Information

Amitiza is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider (HCP) to confirm the absence of such an obstruction prior to initiating Amitiza treatment.

Patients taking Amitiza may experience nausea. If this occurs, concomitant administration of food with Amitiza may reduce symptoms of nausea. Patients who experience severe nausea should inform their HCP.

Amitiza should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. Patients should be instructed to discontinue Amitiza and inform their HCP if severe diarrhea occurs.

Patients taking Amitiza may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their HCP. Some patients have discontinued therapy because of dyspnea.

In clinical trials of Amitiza (24 mcg twice daily vs placebo; N=1113 vs N=316, respectively) in patients with CIC, the most common adverse reactions (incidence > 4%) were nausea (29% vs 3%), diarrhea (12% vs 1%), headache (11% vs 5%), abdominal pain (8% vs 3%), abdominal distension (6% vs 2%), and flatulence (6% vs 2%).

In clinical trials of Amitiza (24 mcg twice daily vs placebo; N=860 vs N=632, respectively) in patients with OIC, the most common adverse reactions (incidence > 4%) were nausea (11% vs 5%) and diarrhea (8% vs 2%).

In clinical trials of Amitiza (8 mcg twice daily vs placebo; N=1011 vs N=435, respectively) in patients with IBS-C the most common adverse reactions (incidence > 4%) were nausea (8% vs 4%), diarrhea (7% vs 4%), and abdominal pain (5% vs 5%).

Concomitant use of diphenylheptane opioids (e.g., methadone) may interfere with the efficacy of Amitiza.

The safety of Amitiza in pregnancy has not been evaluated in humans. Based on animal data, Amitiza may cause fetal harm. Amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when Amitiza is administered to a nursing woman. Advise nursing women to monitor infants for diarrhea.

Reduce the dosage in CIC and OIC patients with moderate and severe hepatic impairment. Reduce the dosage in IBS-C patients with severe hepatic impairment.

Please visit www.sucampo.com/products for complete Prescribing Information and for further information.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs based on ion channel activators knows as prostones. Discovered by the company's scientific founder, prostones are naturally occurring fatty acid metabolites with unique physiological activities. Sucampo has two marketed products – AMITIZA and RESCULA® – and a pipeline of prostone-based product candidates in clinical development. A global company, Sucampo is headquartered in Bethesda, Maryland, and has operations in the United Kingdom, Switzerland and Japan. For more information, please visit www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG. RESCULA is a registered trademark of R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).

Twitter LinkedIn

8:14AM Sucampo Pharma: Numab Reacquires Advanced Compound from Sucampo (SCMP) 6.62 : Co announced that it has reacquired the rights to ND003, a bispecific anti-IL5RxCD3 antibody fragment for the targeted lysis of eosinophils in severe asthma, from Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc.

6:58AM On The Wires (WIRES) :Sucampo Pharmaceuticals (SCMP) announced the presentation of three posters evaluating AMITIZA (lubiprostone) in opioid-induced constipation. Two posters will be presented at the American College of Gastroenterology Annual Scientific Meeting in San Diego, California on Oct 13 and 15, 2013, and the third poster will be presented at the American College of Clinical Pharmacy Annual Meeting in Albuquerque, New Mexico on Oct 16, 2013.

6:49AM Sucampo Pharma announces clinical data showing that lubiprostone is efficacious and well tolerated in children and adolescents with functional constipation (SCMP) 6.38 : Co announced clinical data showing that lubiprostone is efficacious and well tolerated in children and adolescents with functional constipation. The results were published in the Journal of Pediatric Gastroenterology & Nutrition. The primary endpoint for the open-label, multicenter, safety and efficacy study was spontaneous bowel movement (SBM) frequency during week 1 versus baseline. The mean SBM frequency significantly increased from 1.5 SBMs/week at baseline to 3.1 SBMs/week at week 1. In addition, lubiprostone was associated with statistically significant improvements in SBM frequency from baseline for up to three additional weeks. Patients received four weeks of lubiprostone at doses (12 mcg once daily [QD], 12 mcg twice daily [BID], or 24 mcg [BID]) based on age and weight. Of the 127 patients, 124 were treated and analyzed (12 mcg QD, n = 27; 12 mcg BID, n = 65; 24 mcg BID, n = 32), and 109 completed the study. The mean age of treated patients was 10.2 years, and 52% were male.

Common adverse events ncluded nausea (18.5%), vomiting (12.1%), diarrhea (8.1%), abdominal pain (7.3%), and headache (5.6%). Two patients experienced serious AEs (unrelated abdominal pain; unrelated sickle cell crisis).

6:46AM Sucampo Pharma to present data on AMITIZA (lubiprostone) in opioid-induced constipation at 24th Annual AAPM Meeting; presentation demonstrates that AMITIZA does not affect opioid-induced analgesia, was well-tolerated, and resulted in overall improvement in symptoms in OIC patients (SCMP) 6.20 : Co announced the poster presentation of data evaluating the long-term safety of AMITIZA (lubiprostone) as a treatment for adults with chronic, non-cancer pain suffering from opioid-induced constipation (OIC). This poster presentation demonstrates that AMITIZA does not affect opioid-induced analgesia, was well-tolerated, and resulted in overall improvement in symptoms in OIC patients. Sucampo will present this data at the 24th Annual Clinical Meeting for the American Academy of Pain Management (AAPM) in Orlando, Florida on Friday, September 27, 2013.

Bailed here this afternoon for a 5% loss.

No way I could keep it as it was going down on positive news.

6:09AM Sucampo Pharma announced earlier positive top-line results in Phase 1a trials of cobiprostone and SPI-3608 (SCMP) 6.16 : Co announced the positive top-line results of two recently completed clinical trials, a Phase 1a trial of cobiprostone and a Phase 1a trial of SPI-3608. The studies tested the tolerability and pharmacokinetic profiles versus placebo of the two compounds, both of which were demonstrated to be generally well-tolerated in the tested populations. In total, six doses of cobiprostone were tested. No serious or severe adverse events (AEs) were reported and the most frequently observed AE was mild diarrhea. Co also announced the positive top-line results of SPI-3608 in a Phase 1a single-oral-dose study that demonstrated the drug to be generally well tolerated in healthy volunteers. SPI-3608 is being investigated for the treatment of mild to moderate lumbar spinal stenosis (LSS) and may be investigated for additional indications in the future. The next phase of development for SPI-3608 is expected to begin in the first quarter of 2014.

"Pre-clinical data indicate that cobiprostone induces mucosal barrier repair and prevents mucosal barrier damage, and the fact that it was well-tolerated in this study is extremely encouraging. Even though we have not yet evaluated efficacy in patients, we are looking forward to advancing cobiprostone into Phase 1b later this year... Pre-clinical data on SPI-3608 indicate that the compound is capable of the treatment of spinal stenosis by increasing spinal cord blood flow."

Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the second quarter and six months ended June 30, 2013, on Thursday, August 8, 2013, at 5:00 pm Eastern.

The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day.

Doubled up on my position here over the past two trading sessions.

Looking for positive report on August 8.

Amitiza seems to be gaining market share and will become the "go to" drug for the treatment of opioid-induced constipation.

JMHO

Looks like a very good buying opportunity today.

Q2 earnings should be positive catalyst here over the next week.

~ $SCMP ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$SCMP has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "SCMP" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "SCMP": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=SCMP ~
Search Ihub for "SCMP" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=SCMP ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

1:40AM Sucampo Pharma receives $10 mln milestone payment from Takeda (TKPPY) for first sale of AMITIZA for OIC in the US (SCMP) 6.52 : Sucampo Pharmaceuticals announces that it has received a $10 mln milestone payment from Takeda Pharmaceutical (TKPPY). The milestone payment was triggered by the commercial launch of AMITIZA (24 mcg daily) in the United States for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain. The effectiveness of AMITIZA in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids has not been established.